Evaluating a new formulation of Docetaxel for treating triple negative breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of Nanosomal Docetaxel Lipid Suspension (NDLS) in patients with triple-negative breast cancer. The study compares two doses of NDLS (75 mg/m2 and 100 mg/m2) against the conventional Taxotere® (100 mg/m2). It is a randomized, open-label trial involving 657 patients, with tumor responses assessed using RECIST 1.1 guidelines. The aim is to improve the safety profile of docetaxel by eliminating harmful excipients found in traditional formulations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The patient willing to give written signed and dated informed consent to participate in the study.
2. Patient must have histopathologically or cytologically confirmed triple negative breast cancer.
3. Patients may have received one prior chemotherapy regimen for adjuvant therapy and/or one chemotherapy treatment/regimen for firstline metastatic therapy
4. Patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
5. Have at least one measurable lesion as per the RECIST criteria (version 1.1).
6. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to two
7. Left Ventricular Ejection fraction (LVEF) greater than or equal to 50 percentage as per Echocardiography (ECHO).
8. Patient must have recovered from any toxic effects of previous chemotherapy or radiotherapy as judged by the Investigator.
9. Previous chemotherapy or radiotherapy should be completed 4 weeks prior to start of IMP administration.
10. Patients with life expectancy of at least 6 months.
11. Serum pregnancy test at screening and urine pregnancy test on Day 1 (before randomization) must be negative.
12. Sexually active women, unless surgically sterile or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives \[any hormonal method in conjunction with a secondary method\], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile \[at least 6 months prior to Study drug administration\] sexual partner) for at least four weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
13. Patient with adequate bone marrow, renal and hepatic function.

Exclusion Criteria:

1. Patient who has a history of hypersensitivity reactions to Docetaxel or any other component of formulation or to any drugs formulated with polysorbate 80.
2. Patients with a history of HER2 positive over expression and hormone receptor positive (ER or PR)
3. Patient who is already exposed to Docetaxel injection in metastatic setting.
4. Any of the cardiac conditions like Unstable angina, Myocardial infarction within the past six months, Severe uncontrolled ventricular arrhythmias, Clinically significant pericardial disease, Electrocardiographic evidence of acute ischemia, Patient with evidence of abnormal cardiac conduction (e.g., bundle branch block or heart block) except in whom the disease has been stable for the past six months, History of cardiac disease that met the NYHA Classification class 2 or greater
5. Uncontrolled diabetes or infection.
6. Known history of drug addiction within last one year.
7. Patients with known CNS lesions (brain metastasis or carcinomatous meningitis) except for asymptomatic brain metastases.
8. The receipt of an investigational medicinal product or participation in other drug research study within a period of 30 days prior to the first dose of investigational medicinal Product for the current study.
9. Pre-existing motor or sensory neurotoxicity of a severity greater than or equal to grade two as defined by NCI CTCAE 4.03 criteria.
10. Known case of HIV infection.
11. Any other condition that, in the investigator's judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
12. Patients who are unwilling or unable to follow protocol requirements

Where it's running

• Columbus Regional Research Institute, LLC
  Columbus, Georgia, United States Recruiting
• Cox Medical Center
  Springfield, Missouri, United States Recruiting
• Gabrail Cancer Center
  Canton, Ohio, United States Recruiting
• Kailash Cancer Hospital & Research Centre
  Vadodara, Gujarat, India Recruiting

Study contacts

• Study coordinator: Mr. Prashant Modi
• Email: prashantmodi@lambda-cro.com
• Phone: +917940202375

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pre-Treatment Breast DCE-MRI AI Model to Predict Benefit from Neoadjuvant Chemo in Locally Advanced Triple-Negative Breast Cancer

  This study tests an AI model using pre-treatment breast MRI to see if it can identify which locally advanced triple-negative breast cancer patients will benefit most from neoadjuvant chemotherapy.

  Recruiting Fujian Cancer Hospital · Fuzhou, Fujian and 4 other locations · NCT07880600

• JS212-based therapy for recurrent/metastatic TNBC: as monotherapy or with partners

  This phase 2 study tests JS212 alone or with JS207 or JS001 to see if it helps people with recurrent or metastatic triple-negative breast cancer.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality and 30 other locations · NCT07876557

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• Can older adults with breast cancer tolerate a dense CMF chemo schedule

  This study tests whether giving a condensed CMF chemotherapy regimen is feasible for people 70 and older with breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07768436

• Oral paclitaxel in triple-negative breast cancer before main chemotherapy

  This trial tests whether giving an oral paclitaxel dose-6 in combination with standard epirubicin and cyclophosphamide can be tolerated in women with triple-negative breast cancer before surgery.

  Recruiting Phase 1/2 The Affiliated Hospital Of Guizhou Medical University · Guiyang, Guizhou · NCT07739485

• Granzyme B-PET to see if immunotherapy works in TNBC

  This study will test whether a Granzyme B PET/CT scan can help predict how well immunotherapy will work for adults with locally advanced or metastatic triple-negative breast cancer receiving an immune checkpoint inhibitor.

  Recruiting Fudan University · Shanghai · NCT07705438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.